References
- Efron, B. (1994), “Missing Data, Imputation, and the Bootstrap,” Journal of the American Statistics Association, 426, 463–475.
- Food and Drug Administration (FDA) (2014), The US Food and Drug Administration: In Vitro Companion Diagnostic Devices Guidance for Industry and Food and Drug Administration Staff 2014. Available at http://www.fda.gov/downloads/medicaldevices/deviceregulationandguidance/guidancedocuments/ucm262327.pdf.
- Food and Drug Administration (FDA) (2016), The US Food and Drug Administration: List of Cleared or Approved Companion Diagnostic Devices (In Vitro and Imaging Tools). Available at http://www.fda.gov/medicaldevices/productsandmedicalprocedures/invitrodiagnostics/ucm301431.htm.
- Leisenring, W., Alonzo, T., and Pepe, M. S. (2000), “Comparisons of Predictive Values of Binary Medical Diagnostic Tests for Paired Designs,” Biometrics, 56, 345–351.
- Li, M. J. (2015), “Statistical Consideration and Challenges in Bridging Study of Personalized Medicine,” Journal of Biopharmaceutical Statistics, 25, 397–407.
- Li, M. J., Yu, T. H., and Hu, Y. F. (2015), “The Impact of Companion Diagnostic Device Measurement Performance on Clinical Validation of Personalized Medicine,” Statistics in Medicine, 34, 2222–2234.
- Moskowitz, C. S., and Pepe, M. S. (2006), “Comparing the Predictive Values of Diagnostic Tests: Sample Size and Analysis for Paired Study Designs,” Clinical Trials, 3, 272–279.
- Newcombe, R. G. (1998), “Improved Confidence Intervals for the Difference Between Binomial Proportion Based on Paired Data,” Statistics in Medicine, 17, 2635–2650.
- Sharma, A., Zhang, G., Aslam, S., Yu, K., Chee, M., and Palma, J. F. (2016), “Novel Approach for Clinical Validation of the cobas KRAS Mutation Test in Advanced Colorectal Cancer,” Molecular Diagnosis and Therapy, 20, 231–240.